Summary
Current gene expression profiling by massive parallel RNA sequencing provides insight into relative abundance of RNA molecules but fails to resolve the underlying principles in gene regulation that are reflected in the intracellular kinetics of RNA biogenesis, processing and turnover. In the ERC-StG 'miRLIFE', we have developed a novel technology – SLAMseq – that uncovers a chemically modified nucleoside analog by sequencing. When coupled to metabolic RNA labeling and targeted RNA sequencing, SLAMseq provides unprecedented insights into the intracellular kinetics of gene expression in a rapid, scalable and cost-effective manner. Preliminary data show that the SLAMseq technology can be used to modify other nucleoside analogs and be applied for non-targeted RNA seq protocols. In this PoC, we aim to validate and prove this broader applicability of SLAMseq in order to enable and commercialize genome-wide, time-resolved transcriptomics. In this way, metabolic RNA sequencing will revolutionise biomedical research by providing experimental access to the molecular basis of human malignancies and treatments thereof.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/825710 |
| Start date: | 01-01-2019 |
| End date: | 30-06-2020 |
| Total budget - Public funding: | 150 000,00 Euro - 150 000,00 Euro |
Cordis data
Original description
Current gene expression profiling by massive parallel RNA sequencing provides insight into relative abundance of RNA molecules but fails to resolve the underlying principles in gene regulation that are reflected in the intracellular kinetics of RNA biogenesis, processing and turnover. In the ERC-StG 'miRLIFE', we have developed a novel technology – SLAMseq – that uncovers a chemically modified nucleoside analog by sequencing. When coupled to metabolic RNA labeling and targeted RNA sequencing, SLAMseq provides unprecedented insights into the intracellular kinetics of gene expression in a rapid, scalable and cost-effective manner. Preliminary data show that the SLAMseq technology can be used to modify other nucleoside analogs and be applied for non-targeted RNA seq protocols. In this PoC, we aim to validate and prove this broader applicability of SLAMseq in order to enable and commercialize genome-wide, time-resolved transcriptomics. In this way, metabolic RNA sequencing will revolutionise biomedical research by providing experimental access to the molecular basis of human malignancies and treatments thereof.Status
CLOSEDCall topic
ERC-2018-PoCUpdate Date
27-04-2024
Images
No images available.
Geographical location(s)
